Figure 1.

Serial monthly serological measurements from 349 participants up to 262 days after onset of symptoms with severe acute respiratory syndrome coronavirus 2 infection. Samples from the same participant are linked with thin black lines; dotted red lines represent seroreversion. The gamma-plateau model is superimposed to show antibody trajectories; the predicted antibody trajectory (black line) is the median of the posterior distribution of the best model fit and 95% confidence interval, with (light-blue shading) and without (dark-blue shading) individual effects. A, Spike protein (S) antibody. B, Receptor-binding domain (RBD) antibody. C, Nucleoprotein (N) antibody, with a relatively steep rate of decay. Abbreviation: MSD, Meso Scale Discovery assay.